Dr. Lyudmila A. Bazhenova, MD

Dr. Bazhenova practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Bazhenova's NPI, 1093791006, was assigned on December 21, 2005. Dr. Bazhenova graduated from Nizhny Novgorod State Medical Academy in 1994. Dr. Bazhenova holds California license A76755.

Dr. Bazhenova's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Bazhenova's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Bazhenova is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bazhenova practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bazhenova's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bazhenova is board certified in medical oncology by the American Board of Internal Medicine. Dr. Bazhenova is licensed in California.

Dmand AI lists colorectal cancer and lung cancer among the conditions Dr. Bazhenova treats.

CMS data shows 854 Medicare services from Dr. Bazhenova across 4 procedure codes in 2024, for 112 Medicare patients. Medicare paid $55,618 for them.

CMS counts 112 Medicare patients who saw Dr. Bazhenova in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have cancer, and 68% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bazhenova's median patient age at 70, with 64% women.

In 2024, Dr. Bazhenova wrote 397 Medicare Part D claims for 48 patients. 40% of them were for generic drugs. CMS names the drug for 301 of them, across 9 drugs with 11 or more claims each, at $3,278,195 in total drug cost. In 2023, CMS named 153 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Bazhenova for performance year 2024, reported as part of a group. Dr. Bazhenova accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bazhenova as offering telehealth.

Dmand AI links 131 papers to Dr. Bazhenova, published from 2010 to 2025. 2022 was the busiest year, with 18. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and ErbB Receptors. Dr. Bazhenova has published most often in Clin Cancer Res. Dr. Bazhenova's most frequent co-authors are Karen Lynn Reckamp, MD, David R. Camidge, MD and Gregory Aram Daniels, MD, PhD.

Dmand AI links Dr. Bazhenova to 27 clinical trials, 11 of them phase 2 studies. 11 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. SWOG Cancer Research Network sponsors the most, 5. Open Payments lists research payments to Dr. Bazhenova that name 2 trials.

CMS Open Payments shows 505 general payments to Dr. Bazhenova from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. AstraZeneca Pharmaceuticals LP paid the most, $131,140. It also lists 13 research payments totaling $10,063 from 2016 to 2021, naming 2 clinical trials.

Dmand AI lists 2 awards for Dr. Bazhenova, most recently CMS Stage 1 EHR in 2013.

Dr. Bazhenova graduated from Nizhny Novgorod State Medical Academy in 1994. Dr. Bazhenova is a member of AACR, ASCO, ESMO and IASLC.

Dr. Bazhenova is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.